Effect of Photodynamic Therapy (PDT) on Prostate Cancer

Phase 2

Completed

• Conditions: prostate cancer; Cancer - Prostate

• Registration Number: ACTRN12621000633886
• Lead Sponsor: ational Institute of Integrative Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-27
• Study Completion: 2023-12-29
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 35

Inclusion Criteria

Group A: Men with biopsy proven primary prostate cancer, or local prostate cancer relapse after treatment
Group B: Men with primary prostate cancer, diagnosed by PSMA-PET or MRI scan
Group C: Men with metastatic prostate cancer

Exclusion Criteria

Not planning other treatment or medical interventions, e.g. vaccinations during the 3 month trial period.
porphyria
not able to provide consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of CTC / CTC count by cytology[ at time of blood draw: 12 weeks compared to baseline];urinary proteomics - exploratory:<br>previous pilot study found a total of 462 peptides, corresponding to 86 unique proteins[ 12 weeks compared to baseline]

Secondary Outcome Measures

Name	Time	Method
prostate volume by fluorescent photography[ 12 weeks compared to baseline];safety & tolerability will be assessed by questionnaire, including the International Prostate Symptom Score (IPSS) and our standard research side effects & tolerability questionnaire<br>[ At and after each of the 6 treatments (2 treatments/ wk x 3 spread over 9 weeks)]